1152616-69-7

Upstream product

• 1152617-15-6 2-amino-4-bromopyridine-3-carbonitrile 
• 1152617-18-9 7-bromo-3-(2,2,2-trifluoroethyl)imidazo[1,2-a]pyridine-8-carbonitrile 
• 1361110-63-5 4-[2-chloro-4-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)phenyl]morpholine 
• 1272756-07-6 4-(2-chloro-4-bromophenyl)morpholine 

Relevant academic research and scientific papers

Imidazo[1,2-a]pyridines: Orally active positive allosteric modulators of the metabotropic glutamate 2 receptor

Advanced leads of an imidazopyridine series of positive allosteric modulators of the metabotropic glutamate 2 (mGlu2) receptor are reported. The optimization of in vitro ADMET and in vivo pharmacokinetic properties led to the identification of 27o. With g

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.